Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients.

Wen ZhangCaifeng GongXuenan PengXinyu BiYong-Kun SunJianguo ZhouFan WuHuiying ZengYan WangHui ZhouHong ZhaoJianqiang CaiAiping Zhou

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Sintilimab plus IBI305 was well tolerated and was effective therapy for advanced HCC. Both serum concentrations of CD137 and tumor infiltration of M1 macrophages may serve as potential predictive biomarkers. See related commentary by Cappuyns and Llovet, p. 3405.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
nk cells
risk assessment
human health
drug induced